All-trans retinoic acid in patients with type 2 diabetic nephropathy urinary protein and monocyte chemoattractant protein-1 in.docVIP

 PAGE \* MERGEFORMAT 13 All-trans retinoic acid in patients with type 2 diabetic nephropathy urinary protein and monocyte chemoattractant protein-1 in Of: Cui Yingchun Xu Feng Zhou Wenhua Ma Fuzhe Hsu Chung-ho, in Ning Miao Abstract Objective To observe the all-trans retinoic acid (ATRA) and clinical diabetic nephropathy in early (DN) in patients with urinary protein and monocyte chemoattractant protein 1 (MCP 1) investigate the effects of ATRA on the DN effect. Methods 24 h urinary albumin (UMA) the determination of results, type 2 DN patients were divided into early proteinuria and clinical proteinuria. Each group was further divided into 2 groups: angiotensin receptor antagonist (ARB) treatment group and the ATRA + ARB group. In a period of 24 w study, all patients received valsartan 80 mg / d. ATRA + ARB treatment group took ATRA 10 mg / d. Weekly monitoring of patients 24 h urinary protein, routine biochemical tests, measured before and after treatment UMA, urinary MCP 1, urinary creatinine (Ucr). 24 h urine protein measured by immune nephelometry, UMA and urine MCP 1 by enzyme-linked immunosorbent assay, Ucr with picric acid method. Results of two treatment groups in different periods DN patients, the treatment, fasting plasma glucose (Glu) no significant changes in renal function. Early and clinical DN patients were treated 24 h urine protein, UMA / Ucr and urinary MCP 1/Ucr levels were significantly lower than before treatment (P lt;0.01); ATRA + ARB group and the ARB group after treatment, the situation compared to the former 24 h urine protein, UMA / Ucr and urine levels of MCP 1/Ucr lower (P lt;0.05). During treatment, ATRA was not observed associated with serious adverse reactions. Conclusions based on the application of ARB drugs combined ATRA can more effectively reduce proteinuria in patients, including MCP 1 and inhibition of inflammatory mediators, including, thus delaying the progress of DN. Keywords: all-trans retin